As long as the new levels of support are going higher and higher, it will have its dips here and there which is fine. I think the more exposure the company and its REAL products are getting, potential share holders will see the value of this biotech company. It's products are so useful in the rapidly growing diagnostics market. I just saw this article today:
Here's some highlights that are relevant for ARYC's business:
The global transplant diagnostics market is estimated to grow at a CAGR of 7.0% during the forecast period and is expected to be valued at USD 4.36 billion by 2021 while North America is expected to hold largest market share during the forecast period.
CAGR = compound annual growth rate
The transplant diagnostics market is fairly competitive, with growing number of global and local manufacturers of transplant diagnostic products. Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and F. Hoffman-La Roche Ltd. (Switzerland) were the top three players in the transplant diagnostics market in 2015. Product launches; approvals and product enhancements; agreements, partnerships, and collaborations; geographic expansions are the major strategies adopted by most of the market players to achieve growth in the transplant diagnostics market.
This competitive market is ripe for any one of these larger companies to absorb Arrayit, its patents, and their products
There has been no spike or decline in share volume on a daily basis. It's been steadily climbing with each day having movement within a relatively tight range. Other than a quick P&D back in November, where the decline matched the pump, it has been steady. I have seen absolutely no indication of a decline at this point. I predict another +/-10 million share day tomorrow with ARYC breaking the .01 barrier.
News 
Market Data 
Discover 
